|Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.|
|PMID: 15824107 Owner: NLM Status: MEDLINE|
|We have previously demonstrated the effectiveness of adenovirus-mediated expression of antisense urokinase-type plasminogen activator receptor (uPAR) and matrix metalloproteinase-9 (MMP-9) in inhibiting tumor invasion in vitro and ex vivo. However, the therapeutic effect of the adenovirus-mediated antisense approach was shown to be transient and required potentially toxic, high viral doses. In contrast, RNA interference (RNAi)-mediated gene targeting may be superior to the traditional antisense approach, because the target mRNA is completely degraded and the molar ratio of siRNA required to degrade the target mRNA is very low. Here, we have examined the siRNA-mediated target RNA degradation of uPAR and MMP-9 in human glioma cell lines. Using RNAi directed toward uPAR and MMP-9, we achieved specific inhibition of uPAR and MMP-9. This bicistronic construct (pUM) inhibited the formation of capillary-like structures in both in vitro and in vivo models of angiogenesis. We demonstrated that blocking the expression of these genes results in significant inhibition of glioma tumor invasion in Matrigel and spheroid invasion assay models. RNAi for uPAR and MMP-9 inhibited cell proliferation, and significantly reduced the levels of phosphorylated forms of MAPK, ERK, and AKT signaling pathway molecules when compared with parental and empty vector/scrambled vector-transfected SNB19 cells. Furthermore, using RNAi to simultaneously target two proteases resulted in total regression of pre-established intracerebral tumor growth. Our results provide evidence that the use of hairpin siRNA expression vectors for uPAR and MMP-9 may provide an effective tool for cancer therapy.|
|Sajani S Lakka; Christopher S Gondi; Dzung H Dinh; William C Olivero; Meena Gujrati; Velidi H Rao; Chrissa Sioka; Jasti S Rao|
Related Documents :
|16146757 - Involvement of smad4, but not of smad2, in transforming growth factor-beta1-induced tro...
12947137 - Inhibition of mmp-9 expression by ppargamma activators in human bronchial epithelial ce...
15716237 - Matrix metalloproteinase expression is related to angiogenesis and histologic grade in ...
17296767 - Matrix metalloproteinase expression and localization in turkey (meleagris gallopavo) du...
21242807 - Differential modulation of immunostimulant-triggered no production by endoplasmic retic...
10943897 - Rnase ii removes the oligo(a) tails that destabilize the rpso mrna of escherichia coli.
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. Date: 2005-04-11|
|Title: The Journal of biological chemistry Volume: 280 ISSN: 0021-9258 ISO Abbreviation: J. Biol. Chem. Publication Date: 2005 Jun|
|Created Date: 2005-06-06 Completed Date: 2005-08-02 Revised Date: 2009-11-19|
Medline Journal Info:
|Nlm Unique ID: 2985121R Medline TA: J Biol Chem Country: United States|
|Languages: eng Pagination: 21882-92 Citation Subset: IM|
|Departments of Biomedical and Therapeutic Sciences (Program of Cancer Biology), College of Medicine, University of Illinois, Peoria, IL 61656, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Brain Neoplasms / blood supply, metabolism*, pathology
Cell Line, Transformed
Cell Line, Tumor
Collagen / pharmacology
Extracellular Signal-Regulated MAP Kinases / metabolism
Gene Expression Regulation, Enzymologic*
Glioblastoma / metabolism
Glioma / blood supply, metabolism*, therapy
Green Fluorescent Proteins / chemistry, metabolism
Laminin / pharmacology
MAP Kinase Signaling System
Matrix Metalloproteinase 9 / metabolism*
Nucleic Acid Conformation
Promoter Regions, Genetic
Protein Structure, Tertiary
Proteoglycans / pharmacology
RNA, Double-Stranded / genetics*
RNA, Small Interfering / metabolism
Receptors, Cell Surface / metabolism*
Receptors, Urokinase Plasminogen Activator
|CA 75557/CA/NCI NIH HHS; CA 92393/CA/NCI NIH HHS; NS 47699/NS/NINDS NIH HHS|
|0/Drug Combinations; 0/Laminin; 0/PLAUR protein, human; 0/Plaur protein, mouse; 0/Proteoglycans; 0/RNA, Double-Stranded; 0/RNA, Small Interfering; 0/Receptors, Cell Surface; 0/Receptors, Urokinase Plasminogen Activator; 119978-18-6/matrigel; 147336-22-9/Green Fluorescent Proteins; 9007-34-5/Collagen; EC 220.127.116.11/Extracellular Signal-Regulated MAP Kinases; EC 18.104.22.168/Matrix Metalloproteinase 9|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel role for cyclin-dependent kinase 2 in neuregulin-induced acetylcholine receptor epsilon subuni...
Next Document: Hydralysins, a new category of beta-pore-forming toxins in cnidaria.